Replimune (REPL) Gains from Investment Securities (2017 - 2018)
Replimune (REPL) posted Gains from Investment Securities of $2000.0 for Q3 2018, down 99.96% sequentially from $5.4 million in Q2 2018, and down 99.65% YoY from $578000.0 in Q3 2017.
Powered by 
Analysis
Replimune (REPL) Gains from Investment Securities (2017 - 2018) Analysis & Trends
Replimune has reported Gains from Investment Securities for 2 years, with the latest figure at $2000.0 in Q3 2018.
- Quarterly Gains from Investment Securities fell 99.65% year-over-year to $2000.0 in Q3 2018, while the trailing twelve-month figure through Jun 2019 was $2000.0 (down 99.97% YoY) and the FY2019 annual result came in at $5.5 million, up 460.91% from the prior year.
- Gains from Investment Securities fell to $2000.0 in Q3 2018 per REPL's latest filing, from $5.4 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $5.4 million in Q2 2018 and troughed at $2000.0 in Q3 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2018 | 2,000.00 |
| Jun 30, 2018 | 5.45 Mn |
| Mar 31, 2018 | 7,000.00 |
| Dec 31, 2017 | 387,000.00 |
| Sep 30, 2017 | 578,000.00 |